Targeting RORγt

The IMU-935 program comprises one lead compound and a family of orally available small molecule inhibitors of RORγt.
RORγt is a nuclear receptor responsible for gene expression of important cytokines which are involved in various immune or autoimmune diseases. The IMU-935 program, currently in preclinical development, is expected to enter clinical phase 1 trials in mid-2019.